Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Option Care Health ( (OPCH) ) just unveiled an announcement.
On January 12, 2026, Option Care Health released preliminary unaudited results indicating fourth-quarter 2025 net revenue between $1.46 billion and $1.47 billion, GAAP net income of $59.1 million to $62.4 million, and adjusted EBITDA of $123.7 million to $127.7 million, with full-year 2025 net revenue expected at $5.645 billion to $5.655 billion, GAAP net income of $208.2 million to $211.5 million, adjusted diluted EPS of $1.72 to $1.76 and adjusted EBITDA of $469.0 million to $473.0 million, alongside cash flow from operations below $320 million. The company also issued preliminary 2026 guidance calling for net revenue of $5.8 billion to $6.0 billion, adjusted diluted EPS of $1.82 to $1.92 and adjusted EBITDA of $480 million to $505 million, and on January 9, 2026 its board doubled the 2025 share repurchase authorization from $500 million to $1.0 billion—after buying back about $307 million of stock in 2025—signaling continued confidence in cash generation and shareholder returns as it prepares to showcase its outlook at the J.P. Morgan Healthcare Conference on January 13, 2026.
The most recent analyst rating on (OPCH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Option Care Health stock, see the OPCH Stock Forecast page.
Spark’s Take on OPCH Stock
According to Spark, TipRanks’ AI Analyst, OPCH is a Outperform.
Option Care Health’s overall stock score reflects strong financial performance and positive technical indicators. The raised guidance and strategic refinancing efforts further bolster its outlook. However, valuation concerns and margin pressures slightly temper the score.
To see Spark’s full report on OPCH stock, click here.
More about Option Care Health
Option Care Health, Inc., listed on Nasdaq as OPCH, is the nation’s largest independent provider of home and alternate site infusion services, employing more than 8,000 staff, including over 5,000 clinicians, and serving patients with acute and chronic conditions across all 50 U.S. states. Leveraging its clinical leadership, specialized infusion expertise and national scale, the company focuses on reimagining the infusion care experience for patients, payers and provider partners in the broader healthcare services market.
Average Trading Volume: 2,039,290
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.07B
See more data about OPCH stock on TipRanks’ Stock Analysis page.